Recent News

Esperto Medical publishes paper on non-invasive, continuous Blood Pressure monitoring - California, July, 2024

UK-based VC Empirical Ventures targets £10M fund to back early-stage science-led startups - UK, April 4, 2024

Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm - UK, March 14, 2024

Albotherm secures £1.6M to develop low carbon cooling for buildings and greenhouses - UK, June 7, 2023

Oxford Immune Algorithmics Welcomes Mark Stevenson - Oxford, UK, May 15, 2023

Mark Stevenson Joins General Atlantic as Senior Advisor Focused on Life Sciences - New York, March 24, 2023

Relation Therapeutics announces launch of flagship integrated wet–dry laboratory at the heart of London’s Knowledge Quarter - London, UK,  February, 22nd 2023

Thermo Fisher Scientific Completes Acquisition of The Binding Site - Boston, MA, USA January, 3rd 2023

Thermo Fisher Scientific to Acquire The Binding Site Group - Boston, MA, USA October, 31st 2022

EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing - Boston, MA, USA September, 30th 2022

The Binding Site appoints Mark Stevenson as Chairperson - Birmingham, U.K. August 23rd 2022

Ingersoll Rand Announces Appointment of Mark Stevenson and Michael Stubblefield to Board of Directors - Davidson, North Carolina, USA August 2nd 2022

Relation Therapeutics, the Active-Graph Machine Learning Drug Discovery Company, Names David Roblin as CEO and Lindsay Edwards as CTO - London, U.K. June 9th 2022